medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2005, Number 4

<< Back Next >>

Ann Hepatol 2005; 4 (4)

Autoimmune-type chronic active hepatitis in children. A report of 23 cases at a Hospital in Northwestern Mexico

Sotelo N, López G

Language: English
References: 33
Page: 255-260
PDF size: 58.52 Kb.


Text Extraction

Introduction: Autoimmune type chronic active hepatitis (AI-CAH) is a rare pediatric disorder whose principal characteristics include hepatocellular dysfunction and active tissue damage with evolution to cirrhosis in 25–30% of cases. Objective: Our aim was to ascertain the evolution of 23 children with AI-CAH treated between 1978 and 2004 at the Hospital Infantil del Estado de Sonora in the Sonora State capital of Hermosillo in northern Mexico. Materials and methods: We conducted a retrospective review that included the following variables: age; sex; personal antecedents; signs and symptoms; laboratory and medical office studies; histologic tissue pattern obtained by biopsy; treatment; evolution, and mortality. Results: Thirteen males and 10 females participated in the study; predominant signs were hyporexia, fatigue-hepatomegalia, and icterus. Ten patients presented moderate anemia and six patients, leukopenia and thrombocytopenia. Eighteen patients presented hypergammaglobulinemia. Twenty three patients had percutaneous (p.c.) liver biopsy, and we observed the following histologic pattern: rupture of the limiting plate; necrotic foci; cholangiolar proliferation, and fibrotic bridges; in addition, four patients demonstrated precirrhotic changes. Twenty one children received prednisone for periods of between 1 and 12 years; in seven cases, children were administered azatioprine. Six children presented histologic, biochemical, and clinical remission, nine experienced biochemical remission but presented inflammatory activity, five abandoned treatment, and three died due to cirrhosis, liver insufficiency, and other complications. Discussion: To date, AI-CAH etiology continues to be unknown, while treatment has not been importantly modified in 50 years and continues to consist of prednisone alone or in association with azathioprine.


REFERENCES

  1. Sherlock S. Inmunología e hígado. En: Wolpert E, Kersenobich D, editores. Temas selectos de hepatología. México: Interamericana 1982: 168-179.

  2. Chernavsky AC, Paladino N, Rubio AE, De Biasio MB, Periolo N, et al. Simultaneous expression of Th 1 cytokines and IL-4 confers severe characteristics to type I autoimmune hepatitis in children. Human Immunol 2004; 65(7): 683-691.

  3. Li DY, Schwarz KB. Autoimmune hepatitis. Adolesc Med 2004; 15(1): 131-143.

  4. Czaja AJ. Autoimmune liver disease. Curr Opin Gastroenterol 2004; 20: 231-240.

  5. Czaja AL. Current concepts in autoimmune hepatitis. Ann Hepatol 2005; 4(1): 6-24.

  6. Evans JS. Acute and chronic hepatitis. In: Wyllie R, Hymas JS, editors. Pediatric gastrointestinal disease. 2nd ed. Philadelphia, PA, USA: W.B. Saunders; 1999: 600-621.

  7. Klein C, Philipp T, Greiner P, Strobelt M, Muller H, Trautwein C, Brandis M, Manns M. Asymptomatic autoimmune hepatitis associated with anti-LC1 autoantibodies. J Pediatr Gastroenterol Nutr 1996; 23: 461-465.

  8. Silverman A, Roy CC, Cozzetto F. Enfermedad hepática crónica. In: Silverman A, Roy CC, Cozzetto F, editors. Pediatric clinical gastroenterology. 1st ed. St. Louis, MO, USA: Mosby; 1974: 367-413.

  9. Birnbaum AH, Keith JB, Pittman NS, McFarlane FY, Rosh JR, Leleiko NS. Recurrence of autoimmune hepatitis in children after liver transplantation. J Pediatr Gastroenterol Nutr 1997; 25: 20-25.

  10. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.

  11. Aguirre-García J. Una nueva clasificación de la hepatitis crónica. Patologia 1994; 32(3): 139-142.

  12. Dudley FFJ, Scheur PJ, Scherlock S. Natural history of hepatitis associated antigen positive chronic liver disease. Lancet 1972; 2: 1388-1393.

  13. Roberts EA. Autoimmune hepatitis. Indian J Pediatr 1995; 62(5): 525-531.

  14. McNair AM, Moloney M, Portmann BC, Williams R, MacFarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998; 93(5): 777-784.

  15. Ben-Ari Z, Schafer Z, Sulkes J, Manjaim V, Tur-Kaspa R, Fainaru M. Alterations in serum leptin in chronic liver disease. Dig Dis Sci 2002; 47(1): 183-189.

  16. Ikuno N, MacKay IR, Jois J, Osmagari K, Rowley MJ. Antimitochondrial autoantibodies in saliva and sera from patients with primary biliary cirrhosis. J Gastroenterol Hepatol 2001; 15(12): 1390-1394.

  17. Ma Y, Okamoto M, Thomas MG, Bogdanos DP, Lopes AR, Portmann B, Underhill J, Durr R, Mieli-Vergani G, Vergani D. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35(3): 658-664.

  18. Fukugawa NK, Liang P, Li M, Ashikaga T, Reddy KR, Krawit EL. Glutathione-S transferase M 1 null genotype in autoimmune hepatitis. Dig Dis Sci 2001; 46(10): 2080-2083.

  19. Maggiore G, Porta G, Bernard O, Hachouel M, Alvarez F, Homberg J-C, Alagille D. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr 1990; 116: 280-282.

  20. Sotelo-Cruz N, López-Cervantes G, Cordero-Olivares A. Utilidad de la biopsia hepática en el estudio del paciente pediátrico. Revisión de 145 casos. Gac Med Mex 1994; 130(2): 75-80.

  21. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002; 35(4): 890-897.

  22. Debray D, Maggiore G, Girardet JP, Mallet E, Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999; 135(1): 111-114.

  23. Perreaux F, Zenaty D, Capron F, Trioche P, Odievre M, Labrune P. Azathioprine induced lung toxicity and efficacy of cyclosporin A in a young girl with type 2 autoimmune hepatitis. Pediatr Gastroenterol Nutr 2000; 31: 190-192.

  24. Jakson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995; 36: 459-461.

  25. Van thiel DH, Wright H, Carroll P, et al. Tracolimus a potential new treatment for autoimmune chronic active hepatitis: results of an open label preliminary trial. Am J Gastroenterol 1995; 90: 771-776.

  26. Vajro P, Hadchovel P, Hadchovel M, Bernard O, Alagille D. Incidence of cirrhosis in children with chronic hepatitis. J Pediatr 1990; 116: 392-396.

  27. Hernández MH, Kovarik P, Whitington PF, Alonso M. Autoimmune hepatitis as a late complication of liver transplantation. J Pediatr Gastroenterol Nutr 2001; 32: 131-136.

  28. Gupta R, Agarwal SR, Jain M, Malhorta V, Sarin SK. Autoimmune hepatitis in the Indian subcontinent: 7 years experience. J Gastroenterol Hepatol 2001; 16(10): 1144-1148.

  29. Yachha SK, Srivastova A, Chetri K, Sarawast VA, Krishnani N. Autoimmune liver disease in children. J Gastroenterol Hepatol 2001; 16(6): 674-677.

  30. Lee YM, Teo EK, Ng TM, Khor C, Fock KM. Autoimmune hepatitis in Singapore: a rare syndrome affecting middle-aged women. J Gastroenterol Hepatol 2001; 16(12): 1384-1389.

  31. Sotelo-Cruz N, López-Cervantes G. Hepatitis crónica activa. Experiencia de diez años en el Hospital Infantil del Estado de Sonora. Bol Clin Hosp Infantil Edo. Sonora 1989; 6(2): 16-19.

  32. Amit G, Cohen P, Ackerman Z. Nitrofurantoin-induced chronic active hepatitis. Isr Med Assoc J 2002; 4(3): 184-186.

  33. Sotelo-Cruz N, López-Cervantes G. Hepatitis crónica activa autoinmune en niños. Experiencia en 20 casos. Rev Mex Pediatr 2002; 69(4): 133-138.




2020     |     www.medigraphic.com